Drug Trial Radar · NCT02441062
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Last checked: Nov 20, 2026Latest source record: Dec 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
122
Actual
Start
Sep 2015
Primary completion
Jan 20, 2020
Study completion Jan 20, 2020
Sponsor
- Lead sponsor
- Sue O'DorisioAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Iowa
- First posted
- May 12, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors. The purpose of this research study is to see if the tumor can be identified using a special procedure called a positron emission tomography (PET) scan and how the results of this imaging procedure will change the management of the tumor.
Conditions
- Neuroendocrine Tumors
- Carcinoid Tumors
- Neuroblastoma
- Medulloblastoma
Interventions
68Ga-DOTATOC PET/CTDrug
Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT ScanTime frame: 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.